💨 Abstract

India is set to lead the global biopharma outsourcing market, with its Contract Development and Manufacturing Organisation (CDMO) industry projected to reach USD 14 billion by 2028, growing at a 14% CAGR. Key strengths include significant cost advantages, a skilled workforce, strong regulatory compliance (585 FDA-approved plants), and over 200,000 annual pharmacy graduates.

Courtesy: theprint.in